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Table A Missing data: number and proportions of patients with complete data by treatment arm [18]. 
Complete at 
ESP                          
(N=99)
MUA                        
(N=201)
ACR                 
(N=203)
COMPLETE- HEALTH RELATED QUALITY OF LIFE
Baseline 95 (95.96%) 199 (99.00%) 200 (98.52%)
3 months 88 (88.89%) 173 (86.07%) 175 (86.21%)
6 months 75 (75.76%) 172 (85.57%) 165 (81.28%)
12 months 86 (86.87%) 178 (88.56%) 175 (86.21%)
Overall 64 (64.65%) 156 (77.61%) 149 (73.40%)
COMPLETE - COSTS
3 months 78 (78.79%) 164 (81.59%) 158 (77.83%)
6 months 71 (71.72%) 155 (77.11%) 150 (73.89%)
12 months 77 (77.78%) 161 (80.10%) 158 (77.83%)
Overall 55 (55.56%) 123 (61.19%) 121 (59.61%)
COMPLETE – BOTH HEALTH RELATED QUALITY OF LIFE AND COSTS
3 months 76 (76.77%) 161 (80.10%) 154 (75.86%)
6 months 68 (68.69%) 152 (75.62%) 144 (70.94%)
12 months 75 (75.76%) 159 (79.10%) 157 (77.34%)
Overall 46 (46.46%) 117 (58.21%) 116 (57.14%)
Table B Missing data: description of economic variables in UKFROST [18]. 
Missing values (%)
Total ESP MUA ACR Range Mean SD
BASELINE VARIABLES
age Age at trial entry 0 0 0 0 30 to 70 54.25 7.72
gender Male or female 0 0 0 0 1,2 63% Female
eq5d_B EQ-5D-5L at baseline 1.79 4.04 0.99 1.48 -0.37 to 1.00 0.43 0.26
OSS_B OSS score at baseline 0.40 0 0.50 0.49 1 to 48 19.89 8.25
Diabetes Diabetic yes/no at baseline 0 0 0 0 1,3 70% No Dia.
alloc Treatment allocation 0 0 0 0 1,3
OUTCOME VARIABLES FOR HEALTH RELATED QUALITY OF LIFE
eq5d_3m EQ-5D-5L at 3 months 13.32 11.1 13.9 13.8 -0.245 to 1.00 0.60 0.26
eq5d_6m EQ-5D-5L at 6 months 18.09 24.2 14.4 18.7 -0.257 to 1.00 0.70 0.23
eq5d_12m EQ-5D-5L at 12 months 12.72 13.1 11.4 13.8 -0.328 to 1.00 0.73 0.26
OUTCOME VARIABLES FOR COSTS
Cost_ESP Costs of ESP ^ 0 0 0 0 59.8 to 768.4 279.46 148.8
Cost_MUA Costs of MUA ^ 0 0 0 0 259.2 to 972.0 424.81 115.5
Cost_ACR Costs of ACR ^ 0 0 0 0 877.3 to 3,082.3 2,170.46 431.1
Cost_PPP Costs of physiotherapy ~ 0 0 0 0 0 to 975.2 209.65 152.9
Cost_add Additional treatments a 0 0 0 0 0 to 167.97 2.83 21.0
Cost_further Further treatments b 0 0 0 0 0 to 1,521.87 41.41 204.2
Cost_other Other treatments c 0 0 0 0 0 to 668 7.18 49.42
Cost_crossovers Treat. after crossover d 0 0 0 0 0 to 125.01 0.50 7.87
Cost_Hosp_INP Inp costs re complicationse 0 0 0 0 0 to 4,926.24 32.85 312.1
Cost_Hosp_OUP Out costs re complicationsf 0 0 0 0 0 to 875.07 19.37 82.71
Cost_GP_pr Costs of GP visits (surgery) 33.0 37.4 31.8 32.0 0 to 822.8 57.26 110.6
Cost GP_phone Costs of GP visits (phone) 34.2 38.3 32.3 34.0 0 to 197.6 6.33 23.01
Cost Nurse_pr Costs of Practice Nurse 36.4 40.4 34.3 36.4 0 to 75.95 2.10 6.54
Cost_Nure_dis Costs of District Nurse 33.8 37.4 32.8 33.0 0 to 380 1.94 21.69
Cost_Physio_c Costs of District Physio 33.4 35.3 32.8 33.0 0 to 1,214.4 56.27 183.1
Cost_OT_c Costs Occupational Therapist 16.9 16.2 16.4 17.7 0 to 282 0.67 13.79
OUTCOMES FOR COSTS EFFECTIVENESS
Total_QALYs Total QALYs over 1 year 26.6 35.3 22.4 26.6 -0.225 to 0.979 0.66 0.207
Total Costs Total Costs over 1 year 40.5 44.4 38.8 40.4 0 to 5,732.54 1,372.36 1,095.99
^For those who had ESP/surgery (MUA/ARCR).                                                                                                                                           
~ Costs of Post Procedure Physiotherapy for those who had surgery (MUA/ARCR).                                                                        
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a Any treatments received before/during receiving randomised treatment.                                                                                           
b Any treatments received after completing randomised treatment.                                                                                                     
c Any non-trial treatments the patient had if they did not start/complete their randomised treatment.                                        
d Cost of further treatments following crossover.                                                                                                                                       
e Hospital inpatient stay costs related to complications.                                                                                                                       
f Outpatient hospital costs related to complications.                                                                                                                                 
g Costs of Adverse event
Figure A. Post imputation distributions 
A1. Total Costs post imnputation
A2. Total QALYs post imputation
Table C. Logistic regression for (i) missingness of costs and QALYs on baseline variables; and (ii) for 
missingness between missing costs and QALYs and observed outcomes [18]. 
Odds ratio in logistic regression for missing data                  
(95% CI)
Missing data on costs Missing data on QALYs
Treatment allocation ~ (MUA vs ESP) 0.80 (0.48 – 1.32) 0.60 (0.34 – 1.05)
Treatment allocation ~  (ACR vs ESP) 0.85 (0.52 – 1.41) 0.71 (0.41 – 1.23)
Gender 1.26 (0.85 - 1.88) 0.87 (0.55 – 1.37)
Age 0.99 (0.97- 1.01) 0.95 (0.93 – 0.98)**
Diabetes 1.11 (0.89 – 1.38) 1.06 (0.82 – 1.35)
EQ-5D at baseline 0.28 (0.14 – 0.57)** 0.31 (0.14 – 0.67)**
QALYs at 3 months     0.003 (0.00 to 0.09)** 0.00 (0.00 to 0.50)**
QALYs at 6 months 0.007 (0.00 to 0.306)** 0.15 (0.0001 to 1.15)
Costs at 3 months 1.00 (0.99 to 1.00) 0.99 (0.99 to 1.00)
Costs at 6 months 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.00)  
** statistically insignificant results (p>0.05)
Table D: Sensitivity analysis (Scenario 6): summary for incremental analysis (ITT), cost-effectiveness  
results and uncertainty of different methods to handle missing data (MUA vs ESP) [18]. 
Incremental 
cost (£) [95% 
CI]
Incremental QALYs  
[95% CI]
ICER                
(£ per QALY)

















Same MNAR parameters in MUA and ESP ~
M1: -10% QoL in both 
arms





M2: +10% cost in both 
arms





M3: -50% QoL in both 
arms
228.605               
(0.94 to 456.27)
0.0713                  
(0.0221 to 0.1206)
3,204 99%
M4: +50% cost in both 
arms




(-0.0138 to 0.0816) 7,665 78%
M5: -10% QoL and +10% 
costs in both arms
234.7271            
(-6.91 to 476.36)
.0413277                 
(-0.004 to 0.087)
5,680 88%
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M6: -50% QoL and +50% 
costs in both arms
259.2152            
(-52.66 to 
571.09)
0.0710225                  
(0.0217 to 0.1203)  3,650             98%
Different MNAR parameters in MUA and ESP
M7: -10% QoL in ESP 228.605               
(0.94 to 456.27)
0.0559849                  
( 0.010 to 0.102)
4,083 96%
M8: -10% QoL in MUA 228.605               
(0.94 to 456.27)
0.0192851                  
( -0.0281 to 0.0667)
11,854 62%
M9: +10% cost in ESP 199.748               
(-32.80 to 
432.29)
0.0338503                  
( -0.0139 to 0.0816) 5,901 82%
M10: +10% cost in MUA 261.540           
(28.02 to 
495.06)
0.0338673                  
( -0.0138 to 0.0816) 7,722 79%
M11: -50% QoL in ESP 228.605               
(0.94 to 456.27)
   0.144459              
(0.101 to 0.188)  
1,582 99%
M12: -50% QoL in MUA 228.605               
(0.94 to 456.27)
-0.0390401             
(-0.0895 to 0.0114)
-5,856 3%
M13: +50% cost in ESP 84.318              
(-171.7 to 
340.42)
0.0337907                  
(-0.0139 to 0.0815) 2,495 87%
M14: +50% cost in MUA 393.28              
(130.9 to 
655.60)
0.0338787                  
( -0.014 to 0.082) 11,608 71%
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Appendix Fig A1: Total Costs post imputation 
82x60mm (150 x 150 DPI) 
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Appendix Fig A2:Total QALYs post imputation 
82x60mm (150 x 150 DPI) 
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1 Cost-effectiveness of surgical treatments compared with early structured 
2 physiotherapy in secondary care for adults with primary frozen shoulder: 








11 A pragmatic multicentre randomised controlled trial (UK FROST) was conducted in the UK 
12 National Health Service (NHS) comparing the cost-effectiveness of commonly used 
13 treatments for adults with primary frozen shoulder in secondary care.
14
15 Methods
16 A cost utility analysis from the NHS perspective was performed. Differences between 
17 manipulation under anaesthesia (MUA), arthroscopic capsular release (ACR) and early 
18 structured physiotherapy plus steroid injection (ESP) in costs (2018 GBP) and quality adjusted 
19 life years (QALYs) at one year were used to estimate the cost effectiveness of the treatments 
20 using regression methods.
21
22 Results
23 ACR was £1,734 more costly than ESP [(95% confidence intervals (CI) £1,529 to £1,938)] and 
24 £1,457 more costly than MUA (95% CI £1,283 to £1,632). MUA was £276 (95% CI £66 to 
25 £487) more expensive than ESP. Overall, ACR had worse QALYs compared with MUA (-
26 0·0293; 95% CI -0·0616 to 0·0030) and MUA had better QALYs compared with ESP (0·0396; 
27 95% CI -·0008 to 0·0800).  At a £20,000 per QALY willingness-to-pay threshold, MUA had the 
28 highest probability of being cost-effective (0·8632) then ESP (0·1366) and ACR (0·0002). The 
29 results were robust to sensitivity analyses.
30
31 Conclusions
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41 Adhesive capsulitis or frozen shoulder is a common disorder affecting 8.2% of men and 10.1% 
42 of women of working age [1], with an estimated cumulative incidence of 2.4 per 1000 
43 population per year [2]. The capsule of the shoulder joint becomes inflamed, then scarred and 
44 contracted causing pain, stiffness and loss of function [3]. 
45
46 A range of treatment options of varying effectiveness and costs are available for the 
47 management of frozen shoulder in secondary care [4]. A survey of specialist health 
48 professionals conducted in the United Kingdom (UK) in 2009 identified three interventions as 
49 being most commonly used: physiotherapy; manipulation under anaesthesia; and arthroscopic 
50 capsular release [5]. The UK national physiotherapy guidelines for frozen shoulder 
51 recommends exercise and manual therapy either in isolation or to supplement with an intra-
52 articular steroid injection [6]. Both manipulation under anaesthesia and capsular release are 
53 expected to facilitate quicker recovery but are costly and invasive and there is a lack of 
54 rigorous evidence [7-9]. 
55
56 The UK FROzen Shoulder Trial (UK FROST) was conducted to provide evidence of clinical 
57 effectiveness and cost-effectiveness of manipulation under anaesthesia, arthroscopic 
58 capsular release and a specific non-surgical pathway designed for the trial to include intra-
59 articular steroid injection and structured physiotherapy using the best available evidence and 
60 consensus from expert shoulder physiotherapists [6,7,10]. We have called this ‘Early’ 
61 Structured Physiotherapy as it is more quickly accessible than the surgery interventions and 
62 the similarly developed pathway of post-procedural physiotherapy that followed surgery. 
63 Therefore, specifically for the purposes of the trial, participants underwent standardised 
64 physiotherapy programmes in all three groups as described in detail elsewhere, early 
65 structured physiotherapy in the non-surgical group and post-procedural physiotherapy in the 
66 tow surgical groups [11].
67
68 The clinical effectiveness results of UKFROST have been reported [12]. In summary, we 
69 sought a target difference of 5 points on the Oxford Shoulder Score (OSS) between early 
70 structured physiotherapy and either surgical treatment, or a difference of 4 points between the 
71 two surgical treatments.  Mean group differences on the OSS at one year were 2·01 points 
72 between participants randomised to capsular release and manipulation under anaesthesia 
73 (95% confidence interval (CI) 0·10 to 3·91), 3·06 points between capsular release and early 
74 structured physiotherapy (95% CI 0·71 to 5·41), and 1·05 points between manipulation under 
75 anaesthesia and early structured physiotherapy (95% CI -1·28 to 3·39). All of the mean 
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76 differences on the assessment of shoulder pain and function (OSS) at the primary endpoint of 
77 one year were less than the target differences. Therefore, none of the three interventions were 
78 considered to be clinically superior.
79
80 To inform decision-making, it is important to identify the cost-effective intervention for the 
81 treatment of frozen shoulder in secondary care. This paper reports on the economic evaluation 
82 conducted alongside the UK FROST trial, which aimed to assess the health-related quality of 
83 life, costs and cost-effectiveness of surgical treatments (manipulation under anaesthesia and 
84 capsular release followed by post-procedural physiotherapy) versus non-surgical treatment 






91 Individual patient data (IPD) collected alongside the UK FROST trial were used to perform a 
92 cost utility analysis. Costs and health benefits were compared for the three groups over one 
93 year, and hence discounting was not required. Costs (2018 price base) were evaluated from 
94 the UK NHS and Personal Social Services perspective. Health benefits were expressed in 
95 terms of quality-adjusted life-years (QALYs), based on patient’s health related quality of life 
96 using the EuroQol-5 Dimensions (EQ-5D-5L) [13,14]. Adjusted differences in mean costs and 
97 mean QALYs at one year were used to estimate the cost-effectiveness of the three treatment 
98 options. The base-case analysis was conducted on the multiple imputed dataset and followed 
99 an intention-to-treat (ITT) approach; thus the treatment groups were compared based on their 
100 initial random allocation irrespective of protocol deviations or withdrawal. The National 
101 Institute for Health and Clinical Excellence (NICE) guidelines were applied to all methods used 
102 for this economic analysis [15]. All analyses and modelling were conducted in StataTM 16 
103 (StataCorp LP, College Station, Texas, USA).
104
105 Trial design, interventions, and economic data collection 
106 UK FROST recruited 503 adults with a clinical diagnosis of frozen shoulder from 35 hospital 
107 sites in the UK between April 2015 and December 2017. Detailed inclusion and exclusion 
108 criteria are published elsewhere [16]. Patients were randomised on a 2:2:1 basis to 
109 manipulation under anaesthesia with steroid injection (n=201), arthroscopic capsular release 
110 (n=203) or early structured physiotherapy with steroid injection (n=99). 
111
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112 For the purposes of the trial, physiotherapy programmes were standardised in all three groups 
113 using the best available evidence and consensus of expert shoulder physiotherapists 
114 [6,7,10,11]. Physiotherapy in all three groups was to be up to 12 sessions unless exceptionally, 
115 the physiotherapist decided that more than 12 sessions were needed. Patients were also 
116 offered an intra-articular steroid (glucocorticoid) injection at the earliest opportunity in the early 
117 structured physiotherapy pathway. The injection was administered with or without imaging 
118 guidance depending on usual practice of the hospital site, as current evidence did not support 
119 superiority of either approach [17]. We did not anticipate that a steroid injection was normally 
120 given as part of post-procedural physiotherapy that followed the two surgical interventions. All 
121 participants were provided with instructions on a graduated home exercise programme 
122 progressing from gentle pendular exercises to firm stretching exercises according to stage, as 
123 is accepted good practice [6, 11]. The development of the standardised physiotherapy 
124 programmes for UK FROST are described in detail elsewhere [11]. 
125
126 Manipulation under anaesthesia and capsular release were performed as day case surgical 
127 procedures. With manipulation under anaesthesia, the surgeon manipulated the affected 
128 shoulder in a controlled fashion to stretch and tear the tight capsule when the patient was 
129 under general anaesthesia; and that was supplemented by an intra-articular steroid injection. 
130 If the manipulation was judged to be incomplete, the surgeons were asked not to cross-over 
131 intra-operatively to do capsular release in order to allow assessment of the outcome of the 
132 manipulation. Arthroscopic capsular release was performed under general anaesthesia to 
133 surgically divide the contracted anterior capsule in the rotator interval; and that was 
134 supplemented with manipulation to complete and confirm optimal capsular release. 
135 Procedures like posterior capsular release were permitted at the discretion of the operating 
136 surgeon and were recorded. 
137
138 All interventions were delivered either by participating surgeons who were familiar with the 
139 surgical procedures or by qualified physiotherapists (i.e. not students or assistants). There 
140 was no minimum number of surgical procedures that the surgeon had to have performed and 
141 no grades of surgeon were excluded. No additional training was required for either programme 
142 of physiotherapy. However, a standardised booklet was used to record the physiotherapy that 
143 participants received in all three trial arms which provided instructions for delivering the early 
144 structured physiotherapy or post-procedural physiotherapy pathways. 
145
146 NHS ethical approval was obtained on 18 November 2014 from the National Research Ethics 
147 Service (NRES Committee North East – Newcastle & North Tyneside 2; Research Ethics 
148 Committee Reference 14/NE/1176). Local site-specific NHS research and development 
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149 approvals were obtained from each participating site. The study was adopted to the UK Clinical 
150 Research Network portfolio (17719). Written informed consent was obtained from all trial 
151 participants by suitably qualified local study personnel at each participating site.
152
153 As detailed in the trial protocol [16], cost and health outcome data were collected prospectively 
154 via patient questionnaires at three months, six months and one year; and via hospital forms 
155 (baseline characteristics, details of surgery, physiotherapy, complications, and hospital care 
156 due to additional and further treatments received before/during/after completing randomised 
157 treatment). Copies of these forms will be included in Supplementary Material published 
158 alongside the NIHR Health Technology Assessment report [18]. 
159
160 Health outcomes and quality adjusted life-years 
161 The main outcome measure for the economic analysis was QALYs based on the EQ-5D-5L 
162 questionnaire. The EQ-5D has been validated for a range of shoulder conditions [19, 20]. The 
163 EQ-5D-5L was completed by trial participants at baseline, three and six months and one year. 
164 The EQ-5D-5L defines health related quality of life in terms of five dimensions: ‘mobility’, ‘self-
165 care’, ‘usual activities’, ‘pain/discomfort’ and ‘anxiety/depression’. Responses in each 
166 dimension are divided into five ordinal levels coded (1) no problems, (2) slight problems, (3) 
167 moderate problems, (4) severe problems and (5) extreme problems/unable to perform. We 
168 used the Van Hout et al. 2012 mapping function to derive utilities [21]. QALYs were calculated 
169 by combining the utility estimates by the duration of time in each health state using the area 
170 under the curve (AUC) method [22]. The difference in mean QALYs between treatments 
171 groups was adjusted for baseline utility [23].   
172
173 Resource use and costs 
174 The cost for each trial participant was calculated by multiplying health care resource use by 
175 the associated unit costs. Total cost comprises the cost of the initial intervention; hospital stays 
176 and outpatient appointments after initial intervention, including physiotherapy; and visits to 
177 primary and community health care professionals over one year. Costs relating to the surgical 
178 interventions was based on operation times, staff, consumables, and length of stay. The 
179 hospital-based staff cost per minute was estimated using PSSRU 2018 (Personal Social 
180 Services Research Unit) data [24]. These unit cost estimates included staff salaries, salary 
181 on-costs, overheads, and capital overheads. Drug tariff per milligram for medications (i.e. 
182 anaesthesia, antibiotics, and steroid injections) were obtained from the British National 
183 Formulary [25]. To cost length of stay we used NHS Reference costs [26] taking the weighted 
184 average inpatient bed-day for all major and intermediate shoulder procedures. Physiotherapy 
185 data (i.e. session duration and staff delivering the session) was collected using physiotherapy 
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186 forms designed for the trial. Physiotherapists cost per hour was estimated using PSSRU 2018 
187 (Bands 5 to 8). The cost of other hospital-based care and for the primary care and community-
188 based services were estimated by applying unit costs from national tariffs to resource volumes. 
189 Other costs included lost productivity measured as number of days off work. The costs of time 
190 taken off work were estimated by applying costs from the Office National Statistics (ONS) [27] 
191 to occupational information derived from self-reported work status information. Table 1 
192 presents the unit costs used to calculate the total cost per patient in the trial. The base-case 
193 analysis included only shoulder related resource use, except for hospital stay, which included 
194 both shoulder and general medical complications that could apply to the affected shoulder.
195
196 Table 1 Unit costs used for the analysis (£, 2018 prices) [18].
197
Item Unit cost (£) Source
PRIMARY AND COMMUNITY CARE
GP visit at GP practice 37 PSSRU 2018 [23]
GP visit at home 94 PSSRU 2018 [23]
GP by phone a 15 PSSRU 2018 [23]
Nurse visit at GP practice 11 PSSRU 2018 [23]
District/ community nurse 38 PSSRU 2018 [23]
Occupational therapist visit 47 PSSRU 2018 [23]
Physiotherapist visit b 57 PSSRU 2018 [25]
HOSPITAL CARE
Inpatient stay (shoulder) c 258 (MUA)
449 (ACR)
NHS Reference Costs 2017-2018 [25]
Inpatient stay (non-shoulder) 384 NHS Reference Costs 2017-2018 [25]
Day case visit (shoulder) c 420 (MUA)
2,512 (ACR)
NHS Reference Costs 2017-2018 [25]
Outpatient visits (shoulder) 125 NHS Reference Costs 2017-2018 [25]
Outpatient visits (non-shoulder) 124 NHS Reference Costs 2017-2018 [25]
Hospital physiotherapy visit 55 NHS Reference Costs 2017-2018 [25]
Other health service visit 74 NHS Reference Costs 2017-2018 [25]
Consultant surgical 108 PSSRU 2018 [23]
Associate specialist 105 PSSRU 2018 [23]
Speciality Registrar 43 PSSRU 2018 [23]
Foundation doctor FY1 32 PSSRU 2018 [23]
Foundation doctor FY2 28 PSSRU 2018 [23]
Physiotherapist B5 35 PSSRU 2018 [23]
Physiotherapist B6 46 PSSRU 2018 [23]
Physiotherapist B7 55 PSSRU 2018 [23]
Physiotherapist above B8 d 72 PSSRU 2018 [23]
Nurse B5 37 PSSRU 2018 [23]
Nurse B6 45 PSSRU 2018 [23]
Nurse B7 54 PSSRU 2018 [23]
MEDICATIONS
Depomedrone 40mg 3 BNF [24]
Depomedrone 80mg 7 BNF [24]
Triamcinolone 40mg 18 BNF [24]
Triamcinolone 80mg 36 BNF [24]
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Bupivacaine 0.5% (10ml) 1 BNF [24]
General anaesthesia 31 BNF [24]
Antibiotics 6 BNF [24]
PRIVATE CARE
Private Non-NHS physiotherapy 50 https://www.capitalphysio.com
Private osteopath 42 https://www.nhs.uk/conditions/osteopathy
Private chiropractitioner 55 https://www.nhs.uk/conditions/chiropractic
Community care service 49 Averaged of three above
Private hospital - night 337 PSSRU 2018 [23]
198 a Durations sourced from Personal Social Research Unit (PSSRU) 2015. b Community Health Services, Physiotherapist, adult, 
199 one to one (currency code A08A1).  c Sum of total expenditure on excess bed days (elective and non-elective) divided by total 
200 activity for HRG codes relating to shoulder: MUA (HD24E; non inflammatory, bone or joint disorders, with CC score 8-11) 
201 ); ACR (HN53A, HN53B, HN53C, HN54A, HN54B, HN54C; major and intermediate procedures for non-trauma with CC 
202 score 4+, 2-3 and 0-1). d PPP form is featured to record staff at or above Band 8. Hence unit cost for physio at or above Band 
203 is estimated as averaged Band 8a (£66) and Band 8b (£78). 
204
205 Handling missing data 
206 We have previously reported details of the approach applied to handle missing data [18, 28] 
207 and we have used the same methods in this study, as described below. Complete case 
208 analysis (CCA) excludes all participants with any missing or incomplete data. Excluding 
209 patients with missing data leads to loss of statistical power and can bias the results [29]. 
210 Multiple imputation (MI) has been recommended as the appropriate method to reflect the 
211 uncertainty in the results of an economic evaluation attributable to missing data [30]. Multiple 
212 imputation assumes that data are missing at random (MAR), i.e. that the probability that data 
213 is unobserved is dependent only on observed variables [31]. We conducted a comprehensive 
214 investigation following missing data guidelines [29, 32, 33] to prove that MAR was a plausible 
215 assumption fitting UK FROST dataset. Thus, incomplete data on costs and QALYs were 
216 imputed using MI with chain equations and predictive mean matching over 60 imputations. 
217 Age, sex, baseline OSS score, diabetes (yes/no) at baseline, baseline utility and all predictors 
218 of missingness were included as an explanatory variable in the imputation models. Mean 
219 estimates of costs and QALYs, variances and CI were obtained using Rubin’s rules [34]. The 
220 MI model was validated using graphical plots to visualise whether the distribution of imputed 
221 data resembles the distribution of original data. We explored possible departures from the 
222 MAR assumption by means of sensitivity analyses, including complete case analysis. this 
223 Additionally, a mixed model, which does not require an imputation process, is also presented 
224 as per the sensitivity analysis.
225
226 Base Case analysis 
227 The base case analysis was conducted on the imputed dataset on an ITT basis. Cost-
228 effectiveness was estimated as the difference in mean costs divided by the difference in mean 
229 QALYs between the trial comparators at twelve months follow-up, using conventional decision 
230 rules and estimating incremental cost-effectiveness ratios (ICERs) as appropriate [35]. The 
Page 12 of 28
https://mc04.manuscriptcentral.com/bjopen


































































231 mean difference estimates and their 95% CI were generated by means of seemingly unrelated 
232 regression (SUREG) adjusted for age, sex, baseline EQ-5D-5L score, baseline OSS score 
233 and diabetes (yes/no). In order to compute the probability of each intervention being cost-
234 effective at a given cost-effective threshold, the SUREG was conducted with a bootstrapping 
235 approach on five imputed datasets to generate 10,000 replicates of incremental costs and 
236 benefits. These replicates were represented graphically as cost-effectiveness acceptability 
237 curves (CEACs). The probability that each intervention is cost-effective is reported at the cost-
238 effectiveness thresholds applied by NICE of £20,000 to £30,000/QALY [14], and a threshold 
239 of £13,000/QALY as suggested by recent research [36,37]. The ICER was re-expressed in 
240 terms of net monetary benefit (NMB) as an estimate of the gain (or loss) in resources of 
241 investing in the intervention when those resources might be used somewhere else. 
242
243 Analyses of uncertainty 
244 The uncertainty around the cost effectiveness results was explored using sensitivity analyses 
245 all of which controlled for the same covariates: (Scenario1) recalculating costs including non-
246 shoulder costs (ITT approach); (Scenario 2) adopting a broader perspective that includes 
247 productivity and private care costs; (Scenario 3) restricting the analyses to complete cases 
248 (ITT approach); (Scenario 4) imputing QALY data at aggregated level rather than at the index-
249 score level; (Scenario 5) mix model approach; and (Scenario 6) missing not at random 




254 Study population and missing data 
255 The baseline study population for the economic analysis was 503 patients: early structured 
256 physiotherapy (n=99), manipulation under anaesthesia (n=201) and capsular release (n=203). 
257 A total of 19 participants fully withdrew from the trial for whom we used multiple imputation 
258 techniques to impute missing economic data. There were 16 participants who crossed over 
259 from their initial randomisation i.e. from early structured physiotherapy to capsular release 
260 (n=7), from manipulation under anaesthesia to early structured physiotherapy (n=4), from 
261 capsular release to early structured physiotherapy (n=2) and from capsular release to 
262 manipulation under anaesthesia (n=3). A total of 369 (73%) participants [156 (78%) in 
263 manipulation, 149 (73%) in capsular release, and 64 (65%) in early structured physiotherapy] 
264 comprised the complete case for utilities i.e. data for all five EQ-5D-5L dimensions were 
265 available for all four assessment time points. Overall, the proportion of participants with 
266 complete economic data (i.e. both costs and QALYs) were similar between treatment groups: 
Page 13 of 28
https://mc04.manuscriptcentral.com/bjopen


































































267 early structured physiotherapy (46.46%), manipulation under anaesthesia (58.21%) and 
268 capsular release (57.14%) (see Appendix, Table A). 
269
270 A description of economic variables in UK FROST and figures representing the distribution of 
271 economic data before and after the imputation can be found in the Appendix (Table B, Figure 
272 A). Missing data was non-monotonic, since in all groups, individuals with missing data at one 
273 follow-up point may provide data subsequently (i.e. more individuals are observed at year one 
274 than in month 6). The results of logistic regression analysis (see Appendix, Table C) showed 
275 that participants with lower EQ-5D-5L at baseline were significantly more likely to have missing 
276 data on costs (OR 0.28; 95% CI 0.14 to 0.57) and QALYs (OR 0.31; 95% CI 0.14 to 0.67). 
277 Baseline age predicted missing data on quality of life (OR 0.95; 95% CI 0.93 to 0.98); sex and 
278 diabetes were associated with missingness but not statistically significant (p> 0.05). Regarding 
279 the association between missingness and the observed outcomes, missing QALYs at one year 
280 were significantly associated with QALYs at three months (OR 0.00; 95% CI 0.00 to 0.50); 
281 whilst missing costs at one year were significantly associated with QALYS at three months 
282 (OR 0.003; 95% CI 0.00 to 0.09) and QALYs at six months (OR 0.007; 95% CI 0.00 to 0.306). 
283
284 Health care resource use and costs 
285 The mean cost of manipulation under anaesthesia was £425 (SD=£115). For 97% of the cases 
286 manipulation was delivered as a day case, only 3% of the cases required hospitalization (only 
287 one night); the average duration of the manipulation was 25.11 minutes (SD=14.20). The 
288 mean cost of arthroscopic capsular release was £2,170 (SD=£431). For 90% of the cases it 
289 was delivered as a day case; 10% of the cases required hospitalization for on average 2.8 
290 nights (median=1; min=1; max=31) in hospital; and the average duration of the intervention 
291 was 76.61 min (SD=24.22). A total of 160 (80%) participants allocated to manipulation under 
292 anaesthesia and 159 (78%) allocated to capsular release received post procedural 
293 physiotherapy. The mean (SD/max) number of sessions was similar for both groups 
294 [manipulation under anaesthesia: 6.42 (4.95/18) vs capsular release: 6.65 (4.81/18)]. The 
295 mean (SD) cost of post procedural physiotherapy was £214 (£157) for manipulation under 
296 anaesthesia compared with £209 (£153) for capsular release. A total of 162 (97%) patients 
297 who had manipulation under anaesthesia received an injection compared with 46 (27%) who 
298 received capsular release. The mean cost of early structured physiotherapy was £260 
299 (SD=£155) [i.e. mean cost of physiotherapy was £217 (SD=£147); mean cost of a steroid 
300 injection was £43 (SD=£32)]. A total of 85 (86%) patients who had early structured 
301 physiotherapy received an injection as part of their treatment. The mean (SD) number of 
302 sessions received in the early structured physiotherapy pathway was 8.28 (3.45), with a 
303 maximum of 15 sessions and a minimum of two. 
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304 Resource use related to primary and community care was slightly higher for the capsular 
305 release group, although differences between the groups appeared small (Table 2). Over the 
306 entire follow up period, a higher proportion of participants in the capsular release group had 
307 more days lost off work.  Inpatient hospital costs related to complications after initial treatment 
308 up to one year was greater for the manipulation group.  However, participants who received 
309 early structured physiotherapy were more likely to need further treatment following their index 
310 intervention and accumulated greater outpatient costs after discharge. Participants in the 
311 capsular release group received fewest further treatments, however, they accumulated 
312 greater total costs over the trial follow-up; as expected, costs of the surgery were the major 
313 cost driver for this group (Table 3). Participants waited a median of 14 days for early structured 
314 physiotherapy, median of 56·5 days for manipulation under anaesthesia, and a median of 71·5 
315 days for capsular release [11]. The longer waiting times were reflected in the actual days off 
316 work and increased productivity costs which were greater for the capsular release arm. Private 
317 costs were similar among the three arms. To note that total costs estimates shown in Table 3 
318 are unadjusted means, and relates to complete cases, therefore there is limited value in 
319 interpreting differences between treatments. Mean differences for each surgical treatment 
320 versus early structured physiotherapy and corresponding 95% CIs, adjusted for patient 
321 covariates, and taking into consideration the correlation between costs and QALYs are shown 
322 in Table 4 (i.e. cost-effectiveness results).  
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324 Table 2 – Average primary and community resource use (shoulder related) and lost days off work per treatment group [18].
325
Resource Type MUA (n=201) ACR (n=203) ESP (n=99)
 
N Mean            
(SD)
Median Missing       
(%)
N Mean            
(SD)
Median Missing       
(%)
N Mean            
(SD)
Median Missing       
(%)
GP surgery Total 137 1.61 (3.04) 0 64 (31.8) 138 1.73 (3.23) 0 65 (32.0) 62 0.90 (1.89) 0 37 (37.4)
    3 months 168 0.82 (1.64) 0 33 (16.42) 171 1.05 (1.97) 0 32 (15.76) 84 0.58 (1.44) 0 15 (15.15)
    6 months 162 0.30 (1.25) 0 39 (19.40) 163 0.49 (1.60) 0 40 (19.70) 76 0.35 (0.89) 0 23 (23.23)
    12 months 169 0.34 (1.20) 0 64. (31.84) 162 0.24 (0.76) 0 65 (32.02) 80 0.25 (0.88) 0 37 (37.37)
GP telephone Total 136 0.54 (2.05) 0 65 (32.3) 134 0.44 (1.1) 0 69 (33.9) 61 0.10 (0.47) 0 38 (38.4)
    3 months 168 0.28 (1.24) 0 3 (16.42) 165 0.32 (0.99) 0 28 (18.72) 82 0.06 (0.33) 0 17 (17.17)
    6 months 162 0.16 (1.13) 0 39 (19.40) 161 0.09 (0.41) 0 42 (20.69) 74 0.03 (0.16) 0 25 (25.25)
    12 months 168 0.05 (0.17) 0 33 (16.42) 162 0.03 (0.22) 0 41 (20.20) 83 0.01 (0.011) 0 16 (16.16)
Physiotherapist  135 0.83 (2.8) 0 66 (32.8) 136 1.25 (3.8) 0 67 (33.0) 64 1.17 (4.0) 0 35 (35.3)
    3 months 167 0.66 (2.26) 0 34 (16.92) 167 0.64 (2.95) 0 36 (17.73) 83 0.42 (1.72) 0 16 (16.16)
    6 months 161 0.14 (0.79) 0 40 (19.90) 161 0.31 (1.24) 0 42 (20.69) 77 0.49 (2.25) 0 22 (22.22)
    12 months 170 0.71 (0.92) 0 31 (15.42) 162 0.31 (1.32) 0 41 (20.20) 83 0.24 (0.22) 0 16 (16.16)
Nurse surgery 132 0.07 (0.3) 0 69 (34.3) 129 0.39 (0.8) 0 74 (36.4) 59 0.05 (0.3) 0 40 (40.4)
    3 months 166 0.2 (0.15) 0 35 (17.41) 165 0.34 (1.09) 0 38 (18.72) 79 0.05 (0.32) 0 20 (20.20)
    6 months 160 0.01 (0.08) 0 41 (20.40) 156 0.08 (0.30) 0 47 (23.15) 75 0.04 (0.26) 0 24 (24.24)
    12 months 165 0.05 (0.29) 0 36 (17.91) 160 0.02 (0.14) 0 43 (21.18) 79 0 (0) 0 20 (20.20)
Community nurse 135 0 (0) 0 66 (32.8) 136 0.12 (0.9) 0 67 (33.0) 62 0 (0) 0 37 (37.4)
    3 months 168 0 (0) 0 33 (16.42) 168 0.07 (0.51) 0 35 (17.24) 83 0 (0) 0 16 (16.16)
    6 months 160 0 (0) 0 41 (20.40) 161 0.07 (0.79) 0 42 (20.69) 75 0 (0) 0 24 (24.24)
    12 months 170 0.01 (0.15) 0 31 (15.42) 161 0 (0)0 42 (20.69) 82 0 (0) 0 17 (17.17)
Occupational Therapy 137 0.09 (0.7) 0 64 (31.8) 137 0.06 (0.7) 0 66 (32.5) 63 0 (0) 0 36 (36.4)
    3 months 168 0.03 (0.46) 0 33 (16.42) 167 0 (0) 0 36 (17.73) 83 0 (0) 0 16 (16.16)
    6 months 161 0 (0) 0 40 (19.90) 162 0.01 (0.08) 0 41 (20.20) 76 0 (0) 0 23 (23.23)
    12 months 171 0.05 (0.48) 0 32 (15.92) 162 0.05 (0.63) 0 41 (20.20) 82 0 (0) 0 19 (19.19)
Lost days off work 105 17.5 (26.4) 6 96 (47.8) 92 32.8 (44.2) 14 111 (54.) 34 11.5 (27.8) 0 65 (65.6)
    3 months 138 12.5 (22.0) 2 63 (31.34) 125 13.3 (23.6) 0 78 (38.42) 61 7.2 (20.6) 0 38 (38.38)
    6 months 132 3.5 (10.5) 0 69 (34.32) 125 10.9 (23.2) 0 78 (38.42) 50 5.2 (18.8) 0 49 (49.49)
    12 months 138 2.8 (13.3) 0 63 (31.34) 129 3.1 (13.1) 0 74 (36.45) 57 3.9 (13.1) 0 42 (42.42)
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327 Table 3 Costs for cases with complete data by trial allocation and cost category (£, 2018-19 prices) related 









MUA surgical procedure 349 (192) 5 (56) 0
ACR surgical procedure 0 1,762 (935) 113 (496)
ESP 7 (59) 1 (13) 260 (155)
Physiotherapy Hospital setting (i.e. PPP) 176 (164) 175 (162) 7 (36)
Physiotherapy Community setting 44 (146) 66 (202) 62 (211)
Further treatments 60 (248 18 (67) 104 (290)
Hospital Inpatient care 43 (361) 34 (334) 9 (48)
Hospital outpatient care 19 (84) 12 (61) 34 (113)
GP at surgery 60 (114) 65 (121) 34 (71)
GP on the phone 8 (31) 7 (17) 1 (7)
Nurse at surgery 1 (3) 4 (9) 0.5 (3)
Community nurse 0 (0) 5 (34) 0 (0)
Occupational therapist 4 (34) 3 (32) 0 (0)
Total NHS shoulder costs (a) 834 (753) 2,271 (902) 599 (359)
Total NHS non- shoulder costs – (b) 182 (229) 196 (304) 242 (366)
Productivity costs – (c) 1,995 (2,999) 3,736 (5,031) 1,309 (3,165)
Private care costs – (d) 31 (118) 21 (111) 40 (144)
Total broader costs (a+b+c+d) 3,201 (3,824) 5,377 (4,240) 1,475 (2,368)
330
331 Health outcomes and quality adjusted life-years
332 The overall distribution of the EQ-5D scores (utilities) for the different follow-up assessments 
333 is illustrated in Figure 1. Patients allocated to manipulation under anesthesia started from a 
334 higher utility value compared to the other groups [manipulation (mean 0.456) vs capsular 
335 release (mean 0.428) vs early structured physiotherapy (mean 0.402)]. Patients allocated to 
336 the surgical groups had similar utility values (adjusted for baseline utility) at 12 months follow 
337 up [capsular release (mean 0.739) vs manipulation under anaesthesia (mean 0.734)]; both 
338 manipulation under anaesthesia and capsular release had better utility values compared to 
339 early structured physiotherapy at 12 months (mean 0.693). QALYs estimates at one year, 
340 when controlling for baseline utility (for available cases), shows that patients allocated to 
341 manipulation under anaesthesia accrued more QALYs than the other two groups: 
342 manipulation under anaesthesia (0.6765) > early structured physiotherapy (0.6492) > capsular 
343 release (0.6475).
344
345 Figure 1 
346
347 Cost-effectiveness analysis 
348 The incremental analysis for the base-case is summarised in Table 4. Compared to early 
349 structured physiotherapy, manipulation under anaesthesia cost a mean of £276 more per 
350 patient (95% CI £66 to £487) and marginally improved health outcomes over the 12 months 
351 [on average 0.0396 more QALYs per participant than structured physiotherapy (95% CI -
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352 0.0008 to 0.0800)]. The resulting ICER for manipulation under anaesthesia was £6,984 per 
353 additional QALY when compared to early structured physiotherapy. Arthroscopic capsular 
354 release is considerably more costly than early structured physiotherapy [on average £1,734 
355 more expensive per participant (95% CI (£1,529 to £1,938)]; and despite the QALY gained by 
356 capsular release participants [on average 0.0396 more QALYs per participant than 
357 physiotherapy (95% CI -0.0008 to 0.0800)] this was not sufficient to support capsular release 
358 as being a cost-effective use of NHS resources when compared with early structured 
359 physiotherapy. Similarly, capsular release is dominated by manipulation under anaesthesia, 
360 with higher mean costs and lower QALYs. As illustrated by the CEAC in Figure 2, at a £20,000 
361 per QALY threshold the probability of manipulation under anaesthesia being cost-effective 
362 was high (86%) compared with early structured physiotherapy (13%) and capsular release 
363 (0%)
364






95% confidence limits (CI)
Difference in costs (£)
MUA vs ESP 276.51              (65.67 to 487.35)
ACR vs ESP 1,733.78          (1,529.48 to 1,938.06)
ACR vs MUA 1,457.26          (1,282.73 to 1,631.79)
Difference in QALYs 
MUA vs ESP 0.0396              (-0.0008 to 0.0800)
ACR vs ESP 0.0103              (-0.0304 to 0.0510)
ACR vs MUA -0.0293         (-0.0616 to 0.0030)
ICER b             
(£ per 
QALY)
Probability           
cost-effective at 
£13,000/QALY
Probability           
cost-effective at 
£20,000/QALY
Probability           
cost-effective at 
£30,000/QALY
MUA 6,984 0.7942 0.8632 0.8978
ACR > 100,000 0.0000 0.0002 0.002
ESP - 0.2058 0.1366 0.1002





371 Sensitivity analysis 
372 Table 5 shows that the base case analysis results were robust to including non-shoulder costs 
373 with manipulation under anaesthesia continuing to be a cost-effective use of NHS resources. 
374 In contrast, cost-effectiveness results were sensitive to a broader perspective scenario, 
375 suggesting the ICER from a wider perspective was higher than the thresholds that NICE 
376 normally consider for reimbursement decisions. Capsular release continued to be dominated 
377 by manipulation under anaesthesia in both costs’ scenarios. Given that capsular release was 
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378 dominated in all scenarios, sensitivity analyses around missing data were restricted to the 
379 comparison of manipulation under anaesthesia compared with early structured physiotherapy 
380 (Table 6). Both multiple imputation and the mixed model agree that manipulation under 
381 anaesthesia is the cost-effective alternative, although mean difference in costs and QALYs 
382 changed according to the method. The mixed model has slightly larger standard errors than 
383 MI in both the incremental costs and QALYs, possibly because of the large number of 
384 parameters to estimate compared with the analysis model post-imputation. Finally, increasing 
385 costs or decreasing QALYs (scenario 6) in both patient groups make little difference to results 
386 (see Appendix, table D). Manipulation under anaesthesia remains the intervention most likely 
387 to be cost-effective even if their imputed QALYS are reduced by 10% or its cost is increased 
388 by 50%. 
389
390
391 Table 5 Sensitivity analysis (Scenario 1 and Scenario 2): Summary for incremental analysis (ITT), cost-
392 effectiveness results and uncertainty under different costs scenarios [18]. 
393
MI of costs (shoulder – 
NHS perspective) and 
QALYs analysis with 
SUREG^                           
Base-Case analysis
MI of costs (shoulder and 
non-shoulder – NHS 
perspective) and QALYS 
analysis with SUREG
SA (Scenario 1)
MI of costs                           
(broader perspective) 




Difference in costs (£) Mean 276 163 1,032
SE 107 113 595
95% CI 66 to 487 -58 to 384 -137 to 2,201
Difference in QALYs Mean 0.039 0.0375 0.0375
SE 0.0206 0.0207 0.0207
95% CI -0.001 to 0.080 -0.0032 to 0.0782 -0.0032 to 0.0781
ICER 6,984  4,336 27,522
ACR vs ESP
Difference in costs (£) Mean 1,734 1,555 4,110
SE 104 112    648
95% CI 1,529 to 1,938 1,335 to 1,775   2,836.20 to 5,383.73
Difference in QALYs Mean 0.0103 0.0080    0.0081
SE 0.0207555 0.0208   0.0208
95% CI -0.0304 to 0.0510 -0.0328 to 0.0488 -0.0327 to 0.0488
ICER 168,613 194,895 507,707
ACR vs MUA
Difference in costs (£) Mean 1,457 1,393 3,078
SE 89 91 548
95% CI 1,282.73 to 1,631.79 1,213 to 1,572 1,999 to 4,157
Difference in QALYs Mean -0.0293 -0.0296 -0.0294
SE 0.0164678 0.0165 0.0165
95% CI -0.0616 to 0.0030 -0.0619 to 0.0028 -0.0618 to 0.0030
ICER ACR dominated by MUA ACR dominated by MUA ACR dominated by MUA
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402 Table 6: Sensitivity analysis (Scenario 3, Scenario 4 and Scenario 5): Summary for incremental analysis 













Difference in costs (£) Mean 339 193     256
SE 136 107 129
95% CI 72 to 606 -14 to 399 2 to 509
Difference in QALYs Mean 0.016 0.0357                         0.030
SE 0.026 0.020 0.022
95% CI -0.034 to 0.066 (-0.004 to 0.076) -0.014 to 0.073
ICER 21,443 5,395 8,562
Probability that MUA is cost-effective 0.48 0.89 0.76






410 Main findings 
411 UK FROST is the largest randomised clinical trial to our knowledge to date that provides robust 
412 evidence on the cost-effectiveness of common surgical interventions followed by post-
413 procedural physiotherapy compared with a non-surgical pathway of early structured 
414 physiotherapy and steroid injection for the treatment of patients with a frozen shoulder. 
415 Participants’ health related quality of life improved with all three treatments during the trial 
416 follow-up. Overall, participants who had manipulation under anaesthesia accrued more 
417 QALYs compared to those who had capsular release and early structured physiotherapy. The 
418 greater costs of capsular release make this intervention difficult to justify. In particular, 
419 capsular release was dominated by manipulation, with higher mean costs and lower QALYs. 
420 Compared to early structured physiotherapy, participants who had capsular release accrued 
421 on average more QALYs, but this was not sufficient to support capsular release as a cost-
422 effective alternative to early structured physiotherapy. At a £20,000 per QALY threshold the 
423 probability of manipulation under anaesthesia being cost-effective was high (86%) compared 
424 with early structured physiotherapy (13%) and capsular release (0%). Therefore, from an NHS 
425 perspective, this is clear evidence that manipulation under anaesthesia is the most cost-
426 effective option and would represent good value for money. 
427 Strengths and weaknesses
428 This analysis presents an up to date estimate of the cost-effectiveness of three common 
429 treatment pathways for the management of frozen shoulder in the NHS setting. The strengths 
430 of this study were the pragmatic design and the recruitment of patients from 35 hospitals 
431 across a range of rural and urban areas, involving 90 surgeons and 285 physiotherapists. 
432 There were minimal exclusion of patients and the rate of crossovers were low. We also used 
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433 very detailed hospital forms designed for the trial, together with multiple sources of cost data 
434 available for the analyses, to permit an exhaustive micro-costing to optimise the accuracy of 
435 the estimation of the treatment costs. The UK FROST trial, therefore, provides timely and 
436 direct evidence of clinical and resource implications for the NHS that may also be 
437 generalisable to other healthcare systems that offer these treatment options. 
438
439 The EQ-5D instrument has been well validated in patients with a frozen shoulder [18,19]. 
440 However, a systematic review identified a lack of use of generic preference-based measures 
441 in existing frozen shoulder clinical studies [7]. The elicitation of the EQ-5D-5L from patients 
442 with frozen shoulder is another strength of our study, providing further evidence on the impact 
443 of this condition on patient’s overall health related quality of life. 
444
445 There are two potential limitations with the analysis. The first relates to the problem of missing 
446 data, which is a common issue in economic evaluations nested within clinical trials. We 
447 conducted a comprehensive analysis of missing data and a number of sensitivity analyses to 
448 test the assumptions we used to impute missing data in our economic models. Sensitivity 
449 analyses showed that results were robust to alternative assumptions on missing data, 
450 indicating that manipulation under anaesthesia continued to be a cost-effective use of NHS 
451 resources. It is therefore highly unlikely that such assumptions regarding missing data will 
452 change the conclusions of our analysis. 
453
454 The second limitation relates to the length of follow-up, as one year could be argued to be too 
455 short to capture the full effects of all the treatments. Clinical effectiveness results showed at 
456 the primary endpoint of 12 months, many participants had improved to nearly full shoulder 
457 functioning, with a median overall OSS of 43 (out of 48), compared with an initial median 
458 overall OSS of 20 points [11]. It is notable that the difference in OSS scores and the difference 
459 in quality of life are found in the same direction, with only a small difference in QALYS 
460 observed across groups. It could be argued that there is a possible trend of the capsular 
461 release group improving over time, which might continue with longer time follow up. This could 
462 be explained by the timing of the delivery of the interventions. However, additional analysis 
463 adjusting for delivery times of interventions confirmed this did not alter the interpretation of the 
464 primary findings, which in turn, also suggests that it is unlikely that any important difference in 
465 QALYs would emerge beyond the trial follow-up [12].  Regarding costs, we are confident that 
466 important costs, including costs of complications, have been captured during the trial follow-
467 up.
468
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469 It is important to consider that all three treatment groups received standardised physiotherapy 
470 specifically designed for the purposes of the trial. This is likely to have resulted in patients 
471 receiving more physiotherapy and possibly steroid injections in the early structured 
472 physiotherapy pathway than would be received routinely in the NHS and consequently 
473 increased its costs. More physiotherapy, however, was also likely to have been received in 
474 both the surgical pathways than that provided in the NHS. Furthermore, the rationale for the 
475 number of physiotherapy sessions that patients were encouraged to receive in the early 
476 structured physiotherapy intervention was to give every opportunity for the physiotherapy to 
477 be effective. Despite this, early structured physiotherapy was not found to be clinically superior 
478 compared with the surgical treatments or to be the most cost-effective option to the NHS. 
479
480 Finally, it should be noted that this study did not take into consideration the economic impact 
481 of hydrodilatation. This is because when we undertook a survey of practice to inform the 
482 design of UK FROST, only 6% of UK practitioners were using hydrodilatation. Consequently, 
483 this was not identified as a priority intervention for evaluation [38]. Its popularity has increased 
484 since then, and although hydrodilatation has been compared with manipulation, capsular 
485 release, and intra-articular steroid injections [39,40] evidence of its effectiveness and cost-
486 effectiveness is inconclusive. 
487
488 Conclusions
489 To the best of our knowledge there is very limited evidence regarding the cost-effectiveness 
490 of the three commonly used treatments for the frozen shoulder that were compared in UK 
491 FROST. We found that while our specifically designed non-surgical pathway of early 
492 structured physiotherapy and steroid injection was the least costly intervention, manipulation 
493 under anaesthesia was the most cost-effective management pathway for the NHS as the extra 
494 cost was good value for money for the benefits gained by patients. Evidence presented from 
495 this economic evaluation should help clinicians discuss treatment options with patients during 
496 shared decision-making and encourage surgeons to use capsular release more selectively 
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